A Phase 1 interventional study of Reformulated OXY (Totowa) (oxycodone HCl) and Reformulated OXY (Wilson) (oxycodone HCl) in Healthy, sponsored by Purdue Pharma LP. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-11-18.
Sponsored by Purdue Pharma LP (part of Knoa Pharma) · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the bioequivalence of a new oxycodone formulation (80 mg) manufactured at the Totowa, NJ facility relative to the formulation (80 mg) manufactured at the Wilson, NC facility in the fasted state.
Oxycodone hydrochloride (oxycodone) is a semi-synthetic opioid analgesic that is effective in the relief of moderate to severe malignant and non-malignant pain.
Purdue Pharma LP is the lead sponsor of 58 studies on the registry; none are open to participants now.
First submitted before Purdue Pharma LP became part of Knoa Pharma.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reformulated OXY 80 mg (Totowa) x 1 dose
Drug: Reformulated OXY (Totowa) (oxycodone HCl)
Reformulated OXY 80 mg (Wilson) x 1 dose
Drug: Reformulated OXY (Wilson) (oxycodone HCl)
Reformulated OXY 80-mg tablet (Totowa) x 1 dose taken without food.
Reformulated OXY 80-mg tablet (Wilson) x 1 dose taken without food.
Cmax - Maximum Observed Plasma Concentration
Bioequivalence based on Cmax
Time frame: Blood samples collected over 72-hour period
AUC0-inf - Area Under Plasma Concentration-time Curve From Time Zero to Infinity (Extrapolated)
Bioequivalence based on AUC0-inf
Time frame: Blood samples collected over 72-hour period
AUC0-t - Area Under Plasma Concentration-time Curve From Time Zero to Time of Last Non-zero Plasma Concentration
Bioequivalence based on AUC0-t
Time frame: Blood samples collected over 72-hour period
23-Jun-2008 (first Informed Consent Form signed) to 19-Aug-2008 (last subject last visit), at 1 site in the US (Honolulu, HI).
| Milestone | Reformulated OXY (Totowa) (Test) First | Reformulated OXY (Wilson) (Reference) First |
|---|---|---|
| Started | 30 | 28 |
| Completed | 26 | 24 |
| Not completed | 4 | 4 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Adverse event | 3 | 3 |
| Milestone | Reformulated OXY (Totowa) (Test) First | Reformulated OXY (Wilson) (Reference) First |
|---|---|---|
| Started | 26 | 24 |
| Completed | 26 | 24 |
| Not completed | 0 | 0 |
Bioequivalence based on Cmax
| ng/mL | Reformulated OXY (Totowa) (Test) | Reformulated OXY (Wilson) (Reference) |
|---|---|---|
| Cmax - Maximum Observed Plasma Concentration | 78.4 ± 20.8 | 78.2 ± 20.2 |
Bioequivalence based on AUC0-inf
| ng*h/mL | Reformulated OXY (Totowa) (Test) | Reformulated OXY (Wilson) (Reference) |
|---|---|---|
| AUC0-inf - Area Under Plasma Concentration-time Curve From Time Zero to Infinity (Extrapolated) | 846 ± 223 | 850 ± 191 |
Bioequivalence based on AUC0-t
| ng*h/mL | Reformulated OXY (Totowa) (Test) | Reformulated OXY (Wilson) (Reference) |
|---|---|---|
| AUC0-t - Area Under Plasma Concentration-time Curve From Time Zero to Time of Last Non-zero Plasma Concentration | 843 ± 223 | 848 ± 191 |
Collected over Ongoing AEs-followed until resolution/30 days after last dose;AEs reported during 7 days following last dose were recorded & followed until resolution or up to 30 days after last dose. All SAEs were followed until resolution or event/sequelae stabilized.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Reformulated OXY (Totowa) (Test) | — | 0/54 (0%) | 29/54 (53.7%) |
| Reformulated OXY (Wilson) (Reference) | — | 0/54 (0%) | 22/54 (40.7%) |
| Event | Reformulated OXY (Totowa) (Test) | Reformulated OXY (Wilson) (Reference) |
|---|---|---|
| HeadacheNervous system disorders | 13/54 | 8/54 |
| NauseaGastrointestinal disorders | 11/54 | 7/54 |
| SomnolenceNervous system disorders | 11/54 | 5/54 |
| VomitingGastrointestinal disorders | 8/54 | 8/54 |
| DizzinessNervous system disorders | 8/54 | 6/54 |
| Abdominal PainGastrointestinal disorders | 4/54 | 6/54 |
| FatigueGeneral disorders | 3/54 | 4/54 |
| Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders | 1/54 | 4/54 |
| Age, Continuous(years) | Randomized Safety Population |
|---|---|
| Mean | 30 ± 9.6 |
| Sex: Female, Male(Participants) | Randomized Safety Population |
|---|---|
| Female | 22 |
| Male | 36 |
The record gives a start of Jun 2008, a primary completion of Aug 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.
Results were first posted in May 2010, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Oxycodone